Evidence map›Paper›PMID 40398322›Full record

ArticleVaccine2025

DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.

Kevin Liaw, Kylie M Konrath, Abigail R Trachtman, Nicholas J Tursi, Ebony N Gary, Cory Livingston, Kaitlyn Flowers, Jacqueline D Chu, Casey E Hojecki, Niklas Laenger and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Kevin LiawVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Kylie M KonrathVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abigail R TrachtmanVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Nicholas J TursiVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ebony N GaryVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Cory LivingstonVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Kaitlyn FlowersVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Jacqueline D ChuVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Casey E HojeckiVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Niklas LaengerVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Biology Department, Saint Joseph's University, Philadelphia, PA 19104, USA.
Madison E McCannaVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Colby J AgostinoVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Neethu ChokkalingamVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Kelly BayrunsVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Sinja KrieteVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Amber KimVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Joyce ParkVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Cara MonastraVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Lucas A PardoVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Sarah JenisonVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Jinwei HuangVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Kathleen MulkaPenn Vet Comparative Pathology Core, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ami PatelVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Daniel W KulpVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: dwkulp@wistar.org.
David B WeinerVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: dweiner@wistar.org.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticlesP01AI165066 · NIAID · WISTAR INSTITUTE · PI DAVID B. WEINER · 2022 to 2026
$5.3M
NCI NIH HHS T32 CA009171NIAID NIH HHS P01 AI165066NIH HHS 75N93019C00051
6 · The paper itself

Abstract

Current influenza vaccines induce mostly strain-specific immunity necessitating annual reformulation and dosing. Here, we developed an improved seasonal influenza vaccine based on A/H1N1/Wisconsin/588/2019. We designed a DNA-launched self-assembling nanoparticle that displayed seven Wisconsin/588/2019 hemagglutinin (HA) head domains (WI19-7mer). WI19-7mer nanovaccine improved heterologous HAI titers and CD8+ cellular responses in mice than DNA encoded HA trimer (WI19 HA). In human antibody repertoire mice, WI19-7mer induced superior breadth to a diverse panel of H1 HAs compared to WI19 HA immunized animals. Cross-reactive HAI titers were maintained better in mice immunized with WI19-7mer than WI19 HA. The WI19-7mer induced improved antibody binding breadth and provided superior protection in a heterologous challenge compared to challenge-matched HA trimer. Addition of the cytokine adjuvant (CTACK) to WI19-7mer significantly improved breadth, HAI, peripheral responses, and protection in heterologous challenge. These data demonstrate that combining nucleic acid delivery, immune focusing, low valency nanoparticle, and mucosal adjuvant for enhanced vaccine effectiveness has broader applications for other viruses.

Indexed as

Adjuvants, ImmunologicHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNanoparticlesOrthomyxoviridae InfectionsVaccines, DNAAnimalsAntibodies, ViralCD8-Positive T-LymphocytesFemaleHumansImmunity, HeterologousImmunogenicity, VaccineInfluenza A Virus, H1N1 SubtypeInfluenza, HumanMiceAdjuvants, ImmunologicAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNanovaccinesVaccines, DNAInfluenzaMucosal adjuvantNanoparticle vaccine

Identifiers

PMID40398322
PMCPMC13288529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.